An open-label extension study to evaluate safety and efficacy of pazopanib in patients with advanced renal cell Carcinoma

Oncology (Switzerland)

Volumn 87, Issue 6, 2014, Pages 342-350

  Sternberg, Cora N ^a   Davis, Ian D ^b   Deen, Keith C ^c   Sigal, Entisar ^c   Hawkins, Robert E ^d  

^a SAN CAMILLO FORLANINI HOSPITAL   (Italy)

^b MONASH UNIVERSITY   (Australia)

^c GLAXOSMITHKLINE   (United States)

^d UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

Angiogenesis inhibition; Cytokine; Efficacy; Overall survival; Pazopanib; Progression free survival; Renal cell carcinoma; Safety

Indexed keywords

PAZOPANIB; ANGIOGENESIS INHIBITOR; PYRIMIDINE DERIVATIVE; SULFONAMIDE;

ABDOMINAL PAIN; ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANOREXIA; ARTICLE; ASTHENIA; CANCER DIAGNOSIS; CANCER FATIGUE; CANCER GRADING; CANCER INCIDENCE; CANCER PAIN; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CANCER THERAPY; CONTROLLED STUDY; COUGHING; DECREASED APPETITE; DIARRHEA; DISEASE COURSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSGEUSIA; FEMALE; HUMAN; HYPERCALCEMIA; HYPERGLYCEMIA; HYPERKALEMIA; HYPERTENSION; HYPOMAGNESEMIA; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; MALE; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY FAILURE; SINGLE BLIND PROCEDURE; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; VOMITING; CARCINOMA, RENAL CELL; CHEMICALLY INDUCED; CLINICAL TRIAL; DISEASE FREE SURVIVAL; DRUG EFFECTS; HAIR COLOR; KAPLAN MEIER METHOD; KIDNEY NEOPLASMS; LYMPH NODE METASTASIS; MIDDLE AGED; PATHOLOGY; RANDOMIZED CONTROLLED TRIAL (TOPIC); SEVERITY OF ILLNESS INDEX; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANOREXIA; CARCINOMA, RENAL CELL; DIARRHEA; DISEASE-FREE SURVIVAL; FEMALE; HAIR COLOR; HUMANS; HYPERTENSION; KAPLAN-MEIER ESTIMATE; KIDNEY NEOPLASMS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NAUSEA; NEOPLASM STAGING; PYRIMIDINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SEVERITY OF ILLNESS INDEX; SULFONAMIDES; TREATMENT OUTCOME;

EID: 84922395032     PISSN: 00302414     EISSN: 14230232     Source Type: Journal    
DOI: 10.1159/000366227     Document Type: Article

References (19)

1. International Agency for Research on Cancer: GLOBOCAN 2012: estimated cancer incidence, mortality and prevalence worldwide in 2012. http://globocan.iarc.fr/Pages/fact-sheets-population.aspx (accessed July 15, 2014).
2. National Cancer Institute: SEER cancer statistics 2014. http://seer.cancer.gov/statfacts/html/kidrp.html (accessed July 15, 2014).
3. Diaz JI, Mora LB, Hakam A: The Mainz classification of renal cell tumors. Cancer Control 1999; 6: 571-579.
4. Nelson EC, Evans CP, Lara PN Jr: Renal cell carcinoma: current status and emerging therapies. Cancer Treat Rev 2007; 33: 299-313.
5. Sulzbacher I, Birner P, Traxler M, Marberger M, Haitel A: Expression of platelet-derived growth factor-Alpha alpha receptor is associated with tumor progression in clear cell renal cell carcinoma. Am J Clin Pathol 2003; 120: 107-112.
6. Takahashi A, Sasaki H, Kim SJ, Tobisu K, Kakizoe T, Tsukamoto T, Kumamoto Y, Sugimura T, Terada M: Markedly increased amounts of messenger RNAs for vascular endothelial growth factor and placenta growth factor in renal cell carcinoma associated with angiogenesis. Cancer Res 1994; 54: 4233-4237.
7. Sternberg CN, Davis ID, Mardiak J, Szczylik C, Lee E, Wagstaff J, Barrios CH, Salman P, Gladkov OA, Kavina A, Zarba JJ, Chen M, McCann L, Pandite L, Roychowdhury DF, Hawkins RE: Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol 2010; 28: 1061-1068.
8. Sternberg CN, Hawkins RE, Wagstaff J, Salman P, Mardiak J, Barrios CH, Zarba JJ, Gladkov OA, Lee E, Szczylik C, McCann L, Rubin SD, Chen M, Davis ID: A randomised, double-blind phase III study of pazopanib in patients with advanced and/or metastatic renal cell carcinoma: final overall survival results and safety update. Eur J Cancer 2013; 49: 1287-1296.
9. European Medicines Agency: European public assessment report (EPAR) for Votrient [updated 2013]. http:// www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/001141/human- med-001337.jsp&mid=WC0b01ac058001d124 (accessed July 15, 2014).
10. Votrient (pazopanib hydrochloride) prescribing information [November 2013]. http://www.accessdata.fda. gov/drugsatfda-docs/label/2013/022465s017lbl.pdf (accessed July 15, 2014).
11. National Cancer Institute: Common terminology criteria for adverse events v3.0. http://ctep.cancer.gov/ protocolDevelopment/electronic-applications/docs/ctcaev3.pdf (accessed July 15, 2014).
12. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG: New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000; 92: 205-216.
13. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-481.
14. Greenwood M: The Natural Duration of Cancer. Reports on Public Health and Medical Subjects. London, Her Majestys Stationery Office, 1926, vol 33, pp 1-26.
15. Hutson TE, Davis ID, Machiels JP, De Souza PL, Rottey S, Hong BF, Epstein RJ, Baker KL, McCann L, Crofts T, Pandite L, Figlin RA: Efficacy and safety of pazopanib in patients with metastatic renal cell carcinoma. J Clin Oncol 2010; 28: 475-480.
16. Motzer RJ, Hutson TE, Cella D, Reeves J, Hawkins R, Guo J, Nathan P, Staehler M, de Souza P, Merchan JR, Boleti E, Fife K, Jin J, Jones R, Uemura H, De Giorgi U, Harmenberg U, Wang J, Sternberg CN, Deen K, McCann L, Hackshaw MD, Crescenzo R, Pandite LN, Choueiri TK: Pazopanib versus sunitinib in metastatic renal-cell carcinoma. N Engl J Med 2013; 369: 722-731.
17. Escudier B, Porta C, Bono P, Powles T, Eisen T, Sternberg CN, Gschwend JE, De Giorgi U, Parikh O, Hawkins R, Sevin E, Negrier S, Khan S, Diaz J, Redhu S, Mehmud F, Cella D: Randomized, controlled, double-blind, crossover trial assessing treatment preference for pazopanib versus sunitinib in patients with metastatic renal cell carcinoma: PISCES study. J Clin Oncol 2014; 32: 1412-1418.
18. GlaxoSmithKline: A randomised, double-blind, placebo controlled, multi-center phase III study to evaluate the efficacy and safety of pazopanib (GW786034) compared to placebo in patients with locally advanced and/or metastatic renal cell carcinoma. http://www.gsk-clinicalstudyregister.com/study/VEG105192#rs (accessed July 15, 2014).
19. Motzer RJ, Hutson TE, McCann L, Deen K, Choueiri TK: Overall survival in renal-cell carcinoma with pazopanib versus sunitinib. N Engl J Med 2014; 370: 1769-1770.